BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24040662)

  • 21. Immunofixation electrophoresis was highly specific for the diagnosis of renal light-chain amyloidosis.
    Zhou FD; Zhang LX; Yao Y; Wang SX; Zou WZ; Liu G; Chen M; Zhao MH
    Am J Med Sci; 2013 Jan; 345(1):18-21. PubMed ID: 22627261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.
    Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO
    Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
    Zhao L; Tian Z; Fang Q
    Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):186-90. PubMed ID: 26926369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current methods of systemic amyloidosis diagnosis and monitoring of its course].
    Rameev VV; Kozlovskaia LV; Malinina EA; Serova AG; Kogarko IN; Kogarko BS; Liubimova NV
    Ter Arkh; 2011; 83(8):48-54. PubMed ID: 21961333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity.
    Palladini G; Russo P; Bosoni T; Sarais G; Lavatelli F; Foli A; Bragotti LZ; Perfetti V; Obici L; Bergesio F; Albertini R; Moratti R; Merlini G
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):80-3. PubMed ID: 19362981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Determination of light chains in serum].
    Hansen CT; Nielsen L; Münster AM; Abildgaard N
    Ugeskr Laeger; 2010 Aug; 172(34):2302-5. PubMed ID: 20727297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of hematopoietic progenitor cell collections using the COBE Spectra version 7 and Amicus version 3.1 for patients with AL amyloidosis.
    Burgstaler EA; Winters JL
    J Clin Apher; 2011; 26(4):186-94. PubMed ID: 21618597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
    Kaufman GP; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Leung N; Dingli D; Lust JA; Lin Y; Kapoor P; Go RS; Zeldenrust SR; Kyle RA; Rajkumar SV; Kumar SK
    Am J Hematol; 2015 Mar; 90(3):181-6. PubMed ID: 25388651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
    Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
    Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Penile ulcers complicating systemic AL amyloidosis: a case report.
    Arun M; Sloan SB; Shelton A; Sanchorawala V
    Amyloid; 2016 Sep; 23(3):203-204. PubMed ID: 27187183
    [No Abstract]   [Full Text] [Related]  

  • 32. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).
    Tandon N; Sidana S; Dispenzieri A; Gertz MA; Lacy MQ; Dingli D; Buadi FK; Fonder AL; Hayman SR; Hwa YL; Hobbs MA; Kapoor P; Gonsalves WI; Leung N; Go RS; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Kumar SK
    Am J Hematol; 2018 Jan; 93(1):17-22. PubMed ID: 28960427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.
    Ishiguro K; Hayashi T; Igarashi T; Maruyama Y; Ikeda H; Ishida T; Shinomura Y
    Int J Hematol; 2015 Aug; 102(2):200-4. PubMed ID: 26016720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between serum levels of free light chain and phenotype of plasma cells in bone marrow in primary AL amyloidosis.
    Shimojima Y; Matsuda M; Gono T; Ishii W; Fushimi T; Hoshii Y; Yamada T; Ikeda S
    Amyloid; 2005 Mar; 12(1):33-40. PubMed ID: 16076609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome.
    Muchtar E; Derudas D; Mauermann M; Liewluck T; Dispenzieri A; Kumar SK; Dingli D; Lacy MQ; Buadi FK; Hayman SR; Kapoor P; Leung N; Chakraborty R; Gonsalves W; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Gertz MA
    Mayo Clin Proc; 2016 Oct; 91(10):1354-1361. PubMed ID: 27712634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Life-threatening hematuria in a hemodialysis patient with systemic light-chain amyloidosis.
    Hsiao PJ; Chiang WF; Chao TK; Lin SH
    Clin Chim Acta; 2015 Dec; 451(Pt B):180-2. PubMed ID: 26434538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic options in systemic AL amyloidosis.
    van Gameren II; Lokhorst H; Hazenberg BP; Vellenga E
    Neth J Med; 2004 Apr; 62(4):106-13. PubMed ID: 15255079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome in renal Al amyloidosis after chemotherapy.
    Pinney JH; Lachmann HJ; Bansi L; Wechalekar AD; Gilbertson JA; Rowczenio D; Sattianayagam PT; Gibbs SD; Orlandi E; Wassef NL; Bradwell AR; Hawkins PN; Gillmore JD
    J Clin Oncol; 2011 Feb; 29(6):674-81. PubMed ID: 21220614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.
    Kaplan B; Golderman S; Aizenbud B; Esev K; Kukuy O; Leiba M; Livneh A; Ben-Zvi I
    Am J Hematol; 2014 Sep; 89(9):882-8. PubMed ID: 24866208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.